Bharat Biotech signs agreements with US, Brazil to export, outsource COVAXIN production

The first interim reading of efficacy data from Phase III will be out in March, according to Bharat Biotech MD and CEO Dr Krishna Ella.

tech2 News Staff February 04, 2021 11:50:50 IST
Bharat Biotech signs agreements with US, Brazil to export, outsource COVAXIN production

An illustration of COVAXIN, the vaccine candidate for COVID-19 developed by Bharath Biotech. Image: Bharath Biotech

India's first indigenous COVID-19 vaccine Covaxin, co-developed by Bharat Biotech along with the Indian Council of Medical Research (ICMR)–National Institute of Virology (NIV), is going to be shipped globally, according to the Indian vaccinemaker. While the vaccine was given emergency use approval by the Drugs Controller General of India in early January, it is still currently in Phase III clinical trials with around 26,000 volunteers around the country and Phase I and II data have shown that is effective against the novel coronavirus.

According to a report in Mint, Chairman and Managing Director of Bharat Biotech Dr Krishna Ella said that the first interim reading of efficacy data from Phase III will be out in March. Recent data from the company indicates the COVAXIN shot is effective against the new SARS-CoV-2 variant that emerged from the UK. However, three other variants are also circulating in the global population currently, originating in South Africa, Brazil and Japan.

USA

Bharat Biotech signed a contract with US biopharmaceutical company Ocugen to co-develop, supply, and sell its COVID-19 vaccine COVAXIN in the USA. While Ocugen prepares to production the vaccine en masse, Bharat Biotech will still supply the initial doses, the exact number of which has yet to be announced.

Ocugen has already begun discussions with Food & Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) in order to get the necessary approvals to introduce the vaccine in the US and make it a part of the country's national inoculation drive. So far, the country has also granted emergency use approval to COVID-19 vaccines from Pfizer-BioNTech and Moderna.

Bharat Biotech has sold the exclusive right to COVAXIN and Ocugen will enjoy the 45 percent of the profits.

Brazil

A team from Brazil's Precisa Medicamentos visited the Bharat Biotech facility in India on 7 and 8 January. The pharma company signed a deal to export the vaccine to Brazil. The Ambassador of Brazil André Aranha Corrêa do Lago has also expressed an interest in getting the vaccine to the South American country.

The government will buy the vaccine for public use while the private market will get the vaccine once approved by ANVISA, the Brazilian regulatory authority.

Updated Date:

also read

COVID-19: Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials in 2-18 age group
India

COVID-19: Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials in 2-18 age group

The company has already conducted trials in the age group of 2-18 for two doses of Covaxin

Cumulative number of COVID-19 vaccine doses administered in India crosses 190 crore
India

Cumulative number of COVID-19 vaccine doses administered in India crosses 190 crore

So far, more than 3.01 crore (3,01,97,120) children in the age group of 12-14 years have been administered the first dose of COVID-19 vaccine.

COVID-19 update: India logs 2,288 new cases, 28.65% lower than yesterday; 10 die in last 24 hours
India

COVID-19 update: India logs 2,288 new cases, 28.65% lower than yesterday; 10 die in last 24 hours

India's COVID-19 daily case positivity rate has now dropped to 0.47 per cent as compared to 0.95 per cent reported a day ago. The weekly positivity rate is currently at 0.79 per cent